ZIVO Zivo Bioscience Inc

$ZIVO — I took a closer look at the new U.S. patent issued this month. The patent covers poultry feed containing LPS derived specifically from Variovorax paradoxus or Rhodobacter sphaeroides at roughly 0.5–5 lb/ton. These appear to be the same organisms/materials ZIVO has actually been developing in its poultry program. The claim is fairly narrow. Potential design-arounds could include another bacterial LPS source, different concentrations, drinking-water administration instead of feed, or a different immune-modulating molecule. ZIVO originally pursued much broader claims, but the patent ultimately issued with only 3 claims and is subject to a terminal disclaimer, suggesting meaningful overlap with ZIVO’s earlier IP. ZIVO had already disclosed these same two bacterial species, poultry feed and overlapping dosage concepts in an earlier patent family

$ZIVO AI's "Take" on the matter: OH, LET IT BE SO!! The Mystery Partnership: In mid-2025 and updated in May 2026, ZIVO Bioscience announced a collaboration with a "leading global animal health company" to evaluate and advance its immune-modulating biological compounds to combat coccidiosis in poultry. Because Merck Animal Health is one of the world's largest providers of poultry vaccines and therapeutics, industry observers frequently speculate that Merck is the undisclosed partner conducting the dosing trials. Coccidiosis Focus: ZIVO’s product is a non-antibiotic treatment designed to protect birds from gut diseases. Major animal health corporations like Merck are actively looking for alternative treatments to antibiotics due to changing regulations and consumer demand, fueling the rumors of a potential future acquisition or out-licensing deal.

$ZIVO Summer is over and definitely past time for the action to begin. As noted the other day, I think some information on coccidiosis testing is due and whether we are moving to negotiation stage to bring this thing to commercial stage. We know it works. The test was about the economics. Cosmetics is from the OTC presentation. Although thats not fully clear who and what there. Something is on the burner. Same with dummies. Gummies as far as I know is the fastest growing delivery method for supplements. So if thats what it takes to sell more ZivoLife, then bring it. It doesnt take that long. Hence the need IMO for ZIVO to bring in other distributors for the algae. There's no question it's better tha spirulina but ZWorldwide has had more than enough time to gain market traction.

$ZIVO hopefully the hurricane doesn’t hit $CYAN . I wouldn’t expect an update from Zivo regardless. What happened to the algae ponds in Peru?

$ZIVO September is finally here! Let's get this last Summer holiday weekend out of the way and get back to business, eh?

$ZIVO I am expecting some type of announcement in Q4. I think the two key things of the announcement will be: 1. Success of the minimal level study 2. What is the partner wanting to do; nothing, further study, extend exclusive relationship, enter into commercial negotiations/relationship. The second point will be the key.

$ZIVO Welp. Looking like another month of nothingness from ZIVO and partner ZWorldwide. Based in the June presentation, I am looking for news coming next month related to dosage testing from animal pharma partner and those result. At this point it is more than 2 dozen tests on coccidiosis. We know the stuff works. Also based on June presentation, sounded like a cosmetics application deal should also be coming in September. As to ZWorldwide, who the hell knows. Gummies maybe. Zivolike is producing zero revenue to the company. So something gotta give there. I am certain CYAN is up and ready to supply whatever quantities are needed. SO LETS GET SOMETHING DONE !